89bio Inc Sustainability Reports
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, specifically focusing on FGF21 analogs (pegozafermin).
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00QKDZ985
3 reports from 2020 to 2024
Company Profile
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, specifically focusing on FGF21 analogs (pegozafermin).
Reports
3 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
